Effects on bone resorption markers of continuing pamidronate or switching to zoledronic acid in patients with high risk bone metastases from breast cancer

BACKGROUND: Switching patients who remain at high risk of skeletal related events (SREs) despite pamidronate to the more potent bisphosphonate zoledronate, may be an effective treatment strategy. As part of a previously reported clinic study in this setting, we evaluated whether biomarkers for bone...

Descripción completa

Detalles Bibliográficos
Autores principales: Hilton, J.F., Clemons, M., Pond, G., Zhao, H., Mazzarello, S., Vandermeer, L., Addison, C.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709351/
https://www.ncbi.nlm.nih.gov/pubmed/29204337
http://dx.doi.org/10.1016/j.jbo.2017.11.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709351/
https://www.ncbi.nlm.nih.gov/pubmed/29204337
http://dx.doi.org/10.1016/j.jbo.2017.11.001

Ejemplares similares